Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Amortization of Deferred Charges (2022 - 2025)

Historic Amortization of Deferred Charges for Madrigal Pharmaceuticals (MDGL) over the last 4 years, with Q3 2025 value amounting to $329000.0.

  • Madrigal Pharmaceuticals' Amortization of Deferred Charges fell 3145.83% to $329000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 3144.07%. This contributed to the annual value of $2.1 million for FY2024, which is 1346.31% down from last year.
  • As of Q3 2025, Madrigal Pharmaceuticals' Amortization of Deferred Charges stood at $329000.0, which was down 3145.83% from $371000.0 recorded in Q2 2025.
  • Madrigal Pharmaceuticals' 5-year Amortization of Deferred Charges high stood at $753000.0 for Q4 2023, and its period low was $178000.0 during Q2 2022.
  • For the 4-year period, Madrigal Pharmaceuticals' Amortization of Deferred Charges averaged around $459714.3, with its median value being $454000.0 (2024).
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first skyrocketed by 21123.6% in 2023, then crashed by 3598.94% in 2024.
  • Quarter analysis of 4 years shows Madrigal Pharmaceuticals' Amortization of Deferred Charges stood at $306000.0 in 2022, then skyrocketed by 146.08% to $753000.0 in 2023, then crashed by 35.99% to $482000.0 in 2024, then crashed by 31.74% to $329000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $329000.0 for Q3 2025, versus $371000.0 for Q2 2025 and $436000.0 for Q1 2025.